Boston Scientific Corp today announced the acquisition of two novel technologies to treat peripheral chronic total occlusions (CTOs). These acquisitions add technology platforms that complement the company’s portfolio of devices for lower extremity peripheral artery disease.

The device maker acquired a re-entry catheter in November 2010 from S.I. Therapies, Ltd, based in Israel. Boston Scientific will also acquire an intraluminal CTO crossing device through its acquisition of Sunnyvale, CA-based ReVascular Therapeutics, Inc, which is expected to close this month. Worldwide launches of these devices in approved markets are planned later this year.

“Having used both devices, I am impressed with their simplicity and effectiveness,” said Dierk Scheinert, MD, Heart Center Leipzig, and professor of medicine at the University of Leipzig. ”Access to these technologies will greatly enhance therapeutic options and provide physicians with new, intuitive solutions for treating challenging CTOs.”

A CTO, which represents a complete artery blockage, typically cannot be treated with standard endovascular devices such as guidewires and other catheter-based technologies. CTO devices enable endovascular treatment in cases that otherwise might require a patient to undergo surgery or lower extremity amputation. By offering both a re-entry and an intraluminal crossing device, Boston Scientific says it will be well positioned to help physicians address the challenges of treating complex peripheral lesions.

“The purchase of these innovative CTO technologies demonstrates a continued commitment to expanding our peripheral interventions business,” said Joe Fitzgerald, senior vice president and president of Boston Scientific’s Endovascular Unit. ”Not only will they augment our products for treating patients with lower extremity peripheral artery disease, but they will strengthen our clinical relationships with customers by offering them additional ways to deliver patient care.”

Boston Scientific president and CEO Ray Elliott noted that the acquisitions are part of the company’s strategic execution of realigning and strengthening its portfolio in areas with high-growth potential. “Our Priority Growth Initiatives include peripheral vascular disease, in which a significant number of patients remain undiagnosed or untreated.”